Spanish flag Español
Medicina Interna Basada en la Evidencia

Portal para médicos

Alergología: avances de 2022/2023

24.10.2023
Título original: Alergologia – postepy 2022/2023
Autor: prof. Maciej Kupczyk (MD, PhD)

Nota: la revisión de las publicaciones abarca el período comprendido entre el 1 de enero de 2022 y el 9 de marzo de 2023.

Cómo citar: Kupczyk M., Alergologia – postepy 2022/2023, Med. Prakt., 2023; 5: 85‑95

Siglas y abreviaturas: AAS — ácido acetilsalicílico, AEH — angioedema hereditario, AINE — antinflamatorios no esteroideos, ALV — alergia a la leche de vaca, anti‑TPO — anticuerpos antitiroperoxidasa, APAAACI — Asia Pacific Association of Allergy, Asthma and Clinical Immunology, DA — dermatitis atópica, EAACI — European Academy of Allergy & Clinical Immunology, EREA — enfermedad respiratoria exacerbada por aspirina, GA2LEN — Global Allergy and Asthma European Network, IC — intervalo de confianza, IECA — inhibidores de la enzima convertidora de la angiotensina, IL — interleucina, ITA — inmunoterapia con alérgenos, ITV — inmunoterapia con veneno, RR — riesgo relativo, RSC — rinosinusitis crónica, RSCcPN — rinosinusitis crónica con poliposis nasal, UCE — urticaria crónica espontánea, WAO —  World Allergy Organization

Bibliografía
  1. Zuberbier T., Abdul Latiff A.H., Abuzakouk M. y cols., The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria, Allergy, 2022; 77: 734‑766
  2. Maurer M., Magerl M., Betschel S. y cols., The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update, Allergy, 2022; 77: 1961‑1990
  3. Wollenberg A., Kinberger M., Arents B. y cols., European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy, J. Eur. Acad. Dermatol. Venereol., 2022; 36: 1409‑1431
  4. Wollenberg A., Kinberger M., Arents B. y cols., European guideline (EuroGuiDerm) on atopic eczema – part II: non‑systemic treatments and treatment recommendations for special AE patient populations, J. Eur. Acad. Dermatol. Venereol., 2022; 36: 1904‑1926
  5. Sturm G.J., Herzog S.A., Aberer W. y cols., ß‑blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy, Allergy, 2021; 76: 2166‑2176
  6. Farraia M., Paciencia I., Castro Mendes F. y cols., Allergen immunotherapy for asthma prevention: a systematic review and meta‑analysis of randomized and non‑randomized controlled studies, Allergy, 2022; 77: 1719‑1735
  7. Ahlbeck L., Ahlberg E., Björkander J. y cols., Intralymphatic immunotherapy with one or two allergens renders similar clinical response in patients with allergic rhinitis due to birch and grass pollen, Clin. Exp. Allergy, 2022; 52: 747‑75
  8. Hoffmann‑Sommergruber K., de las Vecillas L., Dramburg S. y cols., Molecular allergology user’s guide 2.0, EAACI, 2022; https://hub.eaaci.org/resources_guidelines/molecular-allergology-users-guide-2-0/ (acceso: 13.03.2023)
  9. Barber D., Diaz‑Perales A., Escribese M.M. y cols., Molecular allergology and its impact in specific allergy diagnosis and therapy, Allergy, 2021; 76: 3642‑3658
  10. Muraro A., Worm M., Alviani C. y cols., EAACI guidelines: Anaphylaxis (2021 update), Allergy, 2022; 77: 357‑377
  11. Blazowski L., Majak P., Kurzawa R. y cols., A severity grading system of food‑induced acute allergic reactions to avoid the delay of epinephrine administration, Ann. Allergy Asthma Immunol., 2021; 127: 462‑470.e2
  12. Ryan D., Flokstra‑de Blok B.M.J., Clark E. y cols., Allergic and hypersensitivity conditions in non‑specialist care: flow diagrams to support clinical practice, Allergy, 2022; 77: 2618‑2633
  13. Khan D.A, Banerji A., Blumenthal K.G. y cols., Drug allergy: a 2022 practice parameter update, J. Allergy Clin. Immunol. Pract., 2023; 11: 356‑368.e5.
  14. Pagani M., Bavbek S., Alvarez‑Cuesta E. y cols., Hypersensitivity reactions to chemotherapy: an EAACI Position Paper, Allergy, 2022; 77: 388‑403
  15. Bavbek S., Pagani M., Alvarez‑Cuesta E. y cols., Hypersensitivity reactions to biologicals: an EAACI position paper, Allergy, 2022; 77: 39‑54
  16. Muraro A., de Silva D., Halken S. y cols., Managing food allergy: GA2LEN guideline 2022, World Allergy Organ. J., 2022; doi: 10.1016/j.waojou.2022.100 687
  17. Brozek J.L., Firmino R.T., Bognanni A. y cols., World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow’s Milk Allergy (DRACMA) Guideline update – XIV –Recommendations on CMA immu-notherapy, World Allergy Organ. J., 2022; doi: 10.1016/j.waojou.2022.100 646
  18. Rank M.A., Chu D.K., Bognanni A. y cols., The joint task force on practice parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis, J. Allergy Clin. Immunol., 2023; 151: 386‑398
  19. Gevaert P., Omachi T.A., Corren J. y cols., Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials, J. Allergy Clin. Immunol., 2020; 146: 595‑605
  20. Han J.K., Bachert C., Fokkens W. y cols., Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double‑blind, placebo‑controlled, phase 3 trial, Lancet Respir. Med., 2021; 9: 1141‑1153
  21. Bachert C., Han J.K., Desrosiers M. y cols., Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS‑24 and LIBERTY NP SINUS‑52): results from two multicentre, randomised, double‑blind, placebo‑controlled, parallel‑group phase 3 trials, Lancet, 2019; 394: 1638‑1650
  22. Dellon E.S., Rothenberg M.E., Collins M.H. y cols., Dupilumab in adults and adolescents with eosinophilic esophagitis, N. Engl. J. Med., 2022; 387: 2317‑2330
  23. Agache I., Antolin‑Amerigo D., de Blay F. y cols., EAACI position paper on the clinical use of the bronchial allergen challenge: unmet needs and research priorities, Allergy, 2022; 77: 1667‑1684
  24. Skypala I.J., Jeimy S., Brucker H. y cols., Cannabis‑related allergies: an international overview and consensus recommendations, Allergy, 2022; 77: 2038‑2052